Compare · EW vs SMTI
EW vs SMTI
Side-by-side comparison of Edwards Lifesciences Corporation (EW) and Sanara MedTech Inc. (SMTI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both EW and SMTI operate in Industrial Specialties (Health Care), so they compete in similar markets.
- EW is the larger of the two at $50.78B, about 157.5x SMTI ($322.4M).
- EW has been more active in the news (5 items in the past 4 weeks vs 3 for SMTI).
- EW has more recent analyst coverage (25 ratings vs 6 for SMTI).
- Company
- Edwards Lifesciences Corporation
- Sanara MedTech Inc.
- Price
- -
- -
- Market cap
- $50.78B
- $322.4M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Industrial Specialties
- Industrial Specialties
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 5
- 3
- Recent ratings
- 25
- 6
Edwards Lifesciences Corporation
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral surgical valve replacement; aortic heart valves; annuloplasty rings; cardiac cannula devices; beating heart mitral valve repair system for the treatment of degenerative mitral regurgitation, as well as various procedure-enabling platforms to advance minimally invasive surgery. In addition, it offers critical care products, such as hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; pulmonary artery catheters; arterial pressure monitoring products, oximetry central venous catheters, as well as monitoring platforms that display a patient's physiological information; and Acumen Hypotension Prediction Index, which alerts clinicians in advance of a patient developing low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Sanara MedTech Inc.
Sanara MedTech Inc. develops, markets, and distributes wound and skin care products to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical Activated Collagen Adjuvant powder and gel that are used in a range of surgical specialties to help promote patient healing; Biako¯s Antimicrobial Skin and Wound Cleanser, a patented product that disrupts extracellular polymeric substances to eradicate mature biofilm microbes; Biako¯s Antimicrobial Wound Gel, an antimicrobial hydrogel wound dressing helps against planktonic microbes, as well as immature and mature biofilms; and Biako¯s Antimicrobial Skin and Wound Irrigation Solution. It also provides HYCOL Hydrolyzed Collagen Powder and Gel, a medical hydrolysate of Type I bovine collagen for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers; and PULSAR II Advanced Wound Irrigation System, a portable and no touch hydro-mechanical debridement system that removes bacteria and necrotic tissue without disrupting healthy tissue. The company was formerly known as WNDM Medical Inc. and changed its name to Sanara MedTech Inc. in May 2019. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.
Latest EW
- SEC Form 4 filed by Edwards Lifesciences Corporation
- Barclays initiated coverage on Edwards Lifesciences with a new price target
- Edwards Lifesciences to Host Earnings Conference Call on November 4, 2026
- Edwards Lifesciences to Host Investor Event in Conjunction With TCT
- Edwards Lifesciences Receives FDA Approval for AUTUS Valve, the First Surgical Pulmonary Valve for Pediatric Patients
- SVP, Corporate Controller Dahl Andrew M. covered exercise/tax liability with 253 shares, decreasing direct ownership by 2% to 14,615 units (SEC Form 4) to satisfy withholding tax
- CVP, JAPAC Markowitz Wayne covered exercise/tax liability with 923 shares, decreasing direct ownership by 5% to 19,371 units (SEC Form 4) to satisfy tax liability
- CVP, TAVR Lippis Daniel J. exercised 619 shares at a strike of $72.68 and sold $54,169 worth of shares (619 units at $87.51) as part of a pre-agreed trading plan (SEC Form 4)
- CVP, TMTT, Surgical & IHFM Chopra Daveen covered exercise/tax liability with 398 shares, decreasing direct ownership by 0.90% to 43,926 units (SEC Form 4) to satisfy tax liability
- Edwards Lifesciences Comments on TAVR National Coverage Decision
Latest SMTI
- SEC Form 425 filed by Sanara MedTech Inc.
- SEC Form 8-K filed by Sanara MedTech Inc.
- Sanara MedTech Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Other Events
- Chief Executive Officer Yon Seth D covered exercise/tax liability with 3,661 shares, decreasing direct ownership by 3% to 105,885 units (SEC Form 4) (tax withholding)
- SEC Form DEFM14A filed by Sanara MedTech Inc.
- SEC Form 425 filed by Sanara MedTech Inc.
- SEC Form 10-Q filed by Sanara MedTech Inc.
- SEC Form 425 filed by Sanara MedTech Inc.
- Sanara MedTech Inc. filed SEC Form 8-K: Results of Operations and Financial Condition
- Sanara MedTech Inc. Reports Second Quarter 2026 Financial Results (Unaudited)